The probe delivers laser energy in repeated micropulses rather than as one uninterrupted exposure. Each burst is followed by a cooling interval, so the treatment can act on the ciliary body while reducing the duration of continuous heat delivered to nearby tissues. This design is central to the system’s tissue-sparing approach and distinguishes it from continuous energy delivery.
The ciliary body contributes to aqueous humor production, and the amount of aqueous humor influences intraocular pressure. MP-TSCPC applies energy through the sclera to this structure, reducing aqueous humor production and thereby supporting pressure lowering. This mechanism explains why the platform is directed at the ciliary body rather than used as a general treatment across the eye.
Unlike incisional procedures, the system reaches the treatment target through the sclera without creating an incision. Its micropulsed pattern also differs from continuous laser exposure because cooling intervals interrupt energy delivery. Together, these features provide a nonincisional approach to ciliary-body treatment while limiting continuous heat exposure to surrounding ocular tissues.
MP-TSCPC is especially relevant when glaucoma-related intraocular pressure remains difficult to control with medications or conventional procedures. The system is also associated with managing complex or refractory disease, where additional pressure-management options may be needed. It therefore serves as an option within the broader treatment approach for challenging glaucoma cases.
At a conceptual level, treatment consists of positioning the system’s probe against the scleral surface, directing diode-laser energy toward the ciliary body, and delivering that energy as repeated micropulses. The bursts are separated by cooling intervals during exposure. These steps preserve the system’s transscleral, nonincisional route while focusing treatment on the pressure-related target.
The essential treatment components are the MP-TSCPC platform, its probe, a diode-laser source, and the scleral route to the ciliary body. The probe serves as the delivery interface, while the laser supplies micropulsed energy. This combination allows clinicians to apply targeted treatment externally rather than access the ciliary body through an incision.
The immediate therapeutic objective is lower intraocular pressure through reduced aqueous humor production. In clinical context, that pressure-management goal is most important for patients whose glaucoma remains challenging despite medications or conventional procedures. The system expands available options by combining ciliary-body treatment with a nonincisional approach, which is particularly relevant in complex or refractory disease.